Literature DB >> 14670924

FLT3 mutations in childhood acute lymphoblastic leukemia.

Scott A Armstrong1, Meghann E Mabon, Lewis B Silverman, Aihong Li, John G Gribben, Edward A Fox, Stephen E Sallan, Stanley J Korsmeyer.   

Abstract

Activating mutations of the FLT3 receptor tyrosine kinase are common in acute myelogenous leukemia (AML) but are rare in adult acute lymphoblastic leukemia (ALL). We have recently shown that FLT3 is highly expressed and often mutated in ALLs with rearrangement of the mixed lineage leukemia (MLL) gene on chromosome 11q23. Because hyperdiploid ALL samples also show high-level expression of FLT3, we searched for the presence of FLT3 mutations in leukemic blasts from 71 patients with ALL. The data show that approximately 25% (6 of 25) of hyperdiploid ALL samples possess FLT3 mutations, whereas only 1 of 29 TEL/AML1-rearranged samples harbored mutations (P =.04, Fisher exact test). Three mutations are novel in-frame deletions within a 7-amino acid region of the receptor juxtamembrane domain. Finally, 3 samples from patients whose disease would relapse harbored FLT3 mutations. These data suggest that patients with hyperdiploid or relapsed ALL might be considered candidates for therapy with newly described small-molecule FLT3 inhibitors.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14670924     DOI: 10.1182/blood-2003-07-2441

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  69 in total

1.  Intensified chemotherapy without SCT in infant ALL: results from COG P9407 (Cohort 3).

Authors:  ZoAnn E Dreyer; Joanne M Hilden; Tamekia L Jones; Meenakshi Devidas; Naomi J Winick; Cheryl L Willman; Richard C Harvey; I-Ming Chen; Fred G Behm; Jeanette Pullen; Brent L Wood; Andrew J Carroll; Nyla A Heerema; Carolyn A Felix; Blaine Robinson; Gregory H Reaman; Wanda L Salzer; Stephen P Hunger; William L Carroll; Bruce M Camitta
Journal:  Pediatr Blood Cancer       Date:  2014-11-14       Impact factor: 3.167

2.  Genetic aberrations in childhood acute lymphoblastic leukaemia: application of high-density single nucleotide polymorphism array.

Authors:  Sarina Sulong
Journal:  Malays J Med Sci       Date:  2010-07

3.  Human AML-iPSCs Reacquire Leukemic Properties after Differentiation and Model Clonal Variation of Disease.

Authors:  Mark P Chao; Andrew J Gentles; Susmita Chatterjee; Feng Lan; Andreas Reinisch; M Ryan Corces; Seethu Xavy; Jinfeng Shen; Daniel Haag; Soham Chanda; Rahul Sinha; Rachel M Morganti; Toshinobu Nishimura; Mohamed Ameen; Haodi Wu; Marius Wernig; Joseph C Wu; Ravindra Majeti
Journal:  Cell Stem Cell       Date:  2017-01-12       Impact factor: 24.633

Review 4.  Clinical significance of FLT3 in leukemia.

Authors:  Hitoshi Kiyoi; Masamitsu Yanada; Kazutaka Ozekia
Journal:  Int J Hematol       Date:  2005-08       Impact factor: 2.490

Review 5.  DNA microarrays in the diagnosis and management of acute lymphoblastic leukemia.

Authors:  Adolfo A Ferrando; A Thomas Look
Journal:  Int J Hematol       Date:  2004-12       Impact factor: 2.490

6.  Disease diversity and FLT3 mutations.

Authors:  Catherine Choy Smith
Journal:  Proc Natl Acad Sci U S A       Date:  2013-12-09       Impact factor: 11.205

7.  An Optimized Full-Length FLT3/CD3 Bispecific Antibody Demonstrates Potent Anti-leukemia Activity and Reversible Hematological Toxicity.

Authors:  Yik Andy Yeung; Veena Krishnamoorthy; Danielle Dettling; Cesar Sommer; Kris Poulsen; Irene Ni; Amber Pham; Wei Chen; Sindy Liao-Chan; Kevin Lindquist; S Michael Chin; Allison Given Chunyk; Wenyue Hu; Barbra Sasu; Javier Chaparro-Riggers; Ivana Djuretic
Journal:  Mol Ther       Date:  2020-01-14       Impact factor: 11.454

8.  FLT3 kinase inhibitor TTT-3002 overcomes both activating and drug resistance mutations in FLT3 in acute myeloid leukemia.

Authors:  Hayley S Ma; Bao Nguyen; Amy S Duffield; Li Li; Allison Galanis; Allen B Williams; Patrick A Brown; Mark J Levis; Daniel J Leahy; Donald Small
Journal:  Cancer Res       Date:  2014-07-24       Impact factor: 12.701

9.  TTT-3002 is a novel FLT3 tyrosine kinase inhibitor with activity against FLT3-associated leukemias in vitro and in vivo.

Authors:  Hayley Ma; Bao Nguyen; Li Li; Sarah Greenblatt; Allen Williams; Ming Zhao; Mark Levis; Michelle Rudek; Amy Duffield; Donald Small
Journal:  Blood       Date:  2014-01-09       Impact factor: 22.113

10.  DNMT3A mutations are rare in childhood acute myeloid leukemia.

Authors:  Felicitas Thol; Michael Heuser; Frederik Damm; Jan-Henning Klusmann; Katarina Reinhardt; Dirk Reinhardt
Journal:  Haematologica       Date:  2011-06-17       Impact factor: 9.941

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.